Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CRACR2A | Q9BSW2 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33526676 | 0.96 | POLB (0.48) | POLBGRIN1GRIN2ACNR1CNR2 | |
| SCHEMBL33527410 | 0.91 | POLB (0.44) | POLBGRIN1GRIN2ACNR1CNR2 | |
| SCHEMBL33527256 | 0.81 | LMNA (0.48) | POLBGAATP53L3MBTL1 | |
| SCHEMBL31752066 | 0.80 | TP53 (0.37) | POLBCNR2GAAHDAC4HDAC6 | |
| SCHEMBL31753407 | 0.79 | GRN (0.41) | POLBCNR1CNR2TP53L3MBTL1 | |
| SCHEMBL33526182 | 0.79 | L3MBTL1 (0.39) | POLBCNR2GAATP53L3MBTL1 | |
| SCHEMBL33526846 | 0.78 | CARM1 (0.39) | POLBCNR1CNR2TP53L3MBTL1 | |
| SCHEMBL31753527 | 0.78 | TP53 (0.38) | POLBCNR1CNR2GAATP53 | |
| SCHEMBL31752359 | 0.78 | TP53 (0.36) | POLBCNR2GAAHDAC4HDAC6 | |
| SCHEMBL33526694 | 0.78 | TP53 (0.36) | POLBCNR2GAAHDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | POLB 4770/4885GRIN1 1272/4885GRIN2A 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.